Microbiotica Limited news
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) MB310 for the treatment of ulcerative colitis (UC), was funded following an extensive review process
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date.
The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies with ambitious science and the ability to tackle major medical challenges, and Tencent, a gl
- MB097 is a consortium of bacteria at the core of the microbiome signature predictive of patient response to Immune Checkpoint Inhibitor therapy
- Data show potent anti-tumour efficacy in vivo and in vitro
- MB097 is in manufacturing process development for Ph1b study expected to start next year
- MB097 is the first microbiome precision medicine in immuno-oncology, clinically designed in the same patient cohort in which it will be tested
&
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces that MB097 is now in pre-clinical development for treatment of patients not responding to anti-PD1 therapy. Clinical trials are due to begin in 2022. MB097 is clinically designed and experimentally validated.
Studies have shown that the gut microbiome plays a critical and causative role in determining which cancer patients respond to Immune Checkpoint Inhibitor (ICI) therapy. However clinic
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards.
The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include a key new strategic collaboration with Cancer Research UK and Cambridge University Hospitals, progressing lead programme